Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round, with investor details not disclosed. This significant capital influx will support the company’s ongoing research and development efforts in the mRNA therapeutics space.
Establishment and Recognition
Founded in 2021 by leading mRNA scientists from the Chinese Academy of Sciences (CAS), WestGene has quickly made strides in the industry. The company has initiated clinical trials for an EBV-positive tumor mRNA therapeutic vaccine (EBV-mRNA) and a liver cancer mRNA therapeutic vaccine (HBV-mRNA). WestGene’s innovative work has been recognized by the Ministry of Science and Technology (MOST), earning a spot in the 2022 National Disruptive Technology Innovation Competition Finals.
mRNA Sequence Development and Delivery Technology
WestGene has reportedly established the capability to develop mRNA sequences and delivery vectors, leveraging a lipid nanoparticle (LNP) delivery technology based on novel structural lipids. This technological advancement positions the company at the forefront of mRNA therapeutics and vaccine development.
Previous Funding and Support
In December 2022, WestGene successfully raised over USD 20 million in a Series A finance round, with support from Chengdu Wenjiang Emerging Industry Venture Capital Fund, Tigermed, and other investors. This latest funding round further solidifies WestGene’s financial foundation and supports its mission to develop cutting-edge mRNA-based therapies and vaccines.-Fineline Info & Tech
